भाषा:

India is about to get its first indigenous H5N1 vaccine for chickens. The Ministry of Agriculture and Farmers Welfare has announced that Union Minister Shri Shivraj Singh Chouhan will dedicate the “Inactivated H5N1 (Clade 2.3.2.1a) Highly Pathogenic Avian Influenza Vaccine for Chickens”, developed by ICAR-NIHSAD, Bhopal, to the nation on 20 November 2026. For farmers, hatcheries and vets, this could be the biggest change in how bird flu is handled since the first outbreak in 2006. This article covers the losses India has faced, the virus itself, how it spreads, why earlier approaches fell short, and what the new vaccine can and cannot be expected to do.

Infographic: India's first indigenous H5N1 clade 2.3.2.1a chicken vaccine, losses and what to expect

What has been announced (and what has not)

According to the Press Information Bureau release of 18 November 2026, ICAR-NIHSAD (National Institute of High Security Animal Diseases), Bhopal has developed an inactivated H5N1 vaccine against clade 2.3.2.1a for chickens. The release calls it the first of its kind in India against this clade, and states that no specific commercial vaccine is currently available for clade 2.3.2.1a. The vaccine is intended to protect against the 2.3.2.1a strains circulating in India.

Not yet public: the PIB release does not give trial or efficacy figures, dose, schedule, price, production capacity, licensing partners, or the rules under which poultry farms may use it. We will update this article when official details come out. Until then, treat any figure for these that you see on social media as unverified.

Why this matters: the financial cost of bird flu in India

Highly pathogenic avian influenza (HPAI) can kill close to 100% of infected birds in a flock. Numbers from the PIB release give the scale:

  • India first detected HPAI in 2006. Since then more than 500 combined H5N1 and H5N8 outbreaks have been reported.
  • The 2006 outbreak caused estimated direct and indirect losses of Rs 2,200-3,000 crore.
  • An outbreak in Manipur caused losses equal to about 0.5% of that state’s GDP.
  • A major uncontrolled outbreak could cut India’s GDP growth by up to 1.5%, and more than 20% of the poultry population could be at risk.

Those are national numbers. On a farm, the damage is more direct: when HPAI is confirmed, birds in the affected zone are culled, movement and sales stop, and egg and chicken prices fall because of panic, even where birds are healthy. The chicks, feed, medicines and months of labour already invested are lost, and compensation does not cover all of it. For comparison, a Vietnamese study reports that bird flu there destroyed about 50 million poultry in more than 3,000 outbreaks between 2003 and 2019, costing 0.5-1.8% of GDP each year.

The disease: etiology

HPAI is caused by influenza A virus of the family Orthomyxoviridae. Its genome is made of eight segments of RNA, which allows two viruses in the same bird to swap segments (reassortment). Viruses are named by two surface proteins: H (hemagglutinin, which attaches to the host cell and is the main target of protective antibodies) and N (neuraminidase). HPAI viruses are mostly H5 and H7 types, and are notifiable to WOAH.

What makes a virus “highly pathogenic” is largely a feature of the HA protein: a multi-basic cleavage site lets the virus be activated by enzymes found in many organs, so it spreads through the whole body, not just the airways. This is also why vaccine developers often remove that site from the vaccine seed virus (the Vietnamese team did exactly that to make its seed safe).

H5N1 has been spreading in poultry since 1997 (Hong Kong). H5 viruses have evolved into many clades (0 to 9). Clade 2 dominates South Asia. Clade 2.2 was dominant until about 2010 and was replaced by 2.3.2.1, which split into 2.3.2.1a, 2.3.2.1b and 2.3.2.1c. In India, 2.3.2.1a has been the predominant H5N1 clade in poultry since about 2011, which is why the new vaccine targets it.

Epidemiology and disease pattern in India

  • Hosts: chickens are highly susceptible. Ducks and other waterfowl can carry the virus with little or no sign of illness, so infection can go unnoticed (the Bhutan study points to the large duck population and possible under-reporting). The PIB release says clade 2.3.2.1a infections have also been found in other animals including mammals, and in three human cases.
  • How it moves: wild and migratory birds, live-bird markets, illegal or unregulated movement of poultry, and contaminated equipment, vehicles and people. In neighbouring Bhutan, illegal movement of poultry was the main reason outbreaks happened in 2012.
  • Season: most reports in India come in the cooler months, when migratory birds arrive and the virus survives longer in the environment. This is the general pattern reported in India; check your state animal husbandry department for current alerts.
  • Clinical picture in chickens: sudden high mortality, depression, drop in feed and water intake, swollen head and face, bluish comb and wattles, haemorrhages on shanks, respiratory signs, and a steep fall in egg production in layers. In the ICAR-NIHSAD challenge study, unvaccinated chickens infected with the 2.3.2.1a virus died within 60 hours.

States affected over the years. India’s first outbreak was in 2006 (Maharashtra and Gujarat). Later outbreaks have been reported in West Bengal and the north-eastern states (Assam, Tripura, Manipur and others), and in recent years in several states across the country, including Andhra Pradesh, Maharashtra, Kerala, Jharkhand and Haryana, with human cases reported in Haryana (2021) and Andhra Pradesh (2025). Please check the latest state-wise list from the Department of Animal Husbandry and Dairying before quoting it.

A reassortant clade worth knowing about. A study from Bhutan (Emerging Infectious Diseases, 2016) found that the 2012 outbreaks there were caused by a 2.3.2.1a virus carrying an H9-like PB1 gene. This genotype has been reported in Bangladesh, India and Nepal. In the lab it replicated faster and spread to contact chickens more efficiently than its parent genotype, and in ferrets it infected the nose and, in one animal, caused mild brain inflammation, though it did not spread to contact ferrets. This is why genomic surveillance matters.

What the virology problem has been until now

  • The virus keeps changing. Clades replace each other (2.2 to 2.3.2.1 and its subclades). A vaccine made from the wrong clade protects poorly. Vietnam learned this when imported vaccines made for clades 0 and 2.3.4 failed against local 2.3.2.1 viruses.
  • Small differences matter. Between clades 2.3.2.1a and 2.3.2.1c, only 8 amino acids differ in the HA1 region, yet in ICAR-NIHSAD’s own research a recombinant vaccine matched to 2.3.2.1a protected 100% of chickens against 2.3.2.1a but only 50% against 2.3.2.1c.
  • No matched vaccine for 2.3.2.1a. As the PIB release states, there is no specific commercial vaccine for this clade. With no vaccine, the only tool has been stamping out: culling, disposal, disinfection and movement control. It works only if it is fast and complete, and its cost falls on farmers.
  • Dependence on imported seed strains. Many countries rely on imported candidate viruses. A local, quickly updatable platform is the long-term fix (Vietnam showed a reverse-genetics seed can be made in 10-12 weeks).
  • Silent spread. Ducks and partly protected birds can carry and shed virus without looking sick, so surveillance has to continue even with a vaccine.

Technical details: what we know about the vaccine, step by step

  • Type: inactivated (killed) H5N1 vaccine. Inactivated vaccines cannot cause the disease and are given by injection, usually with an oil adjuvant to boost the response.
  • Target: clade 2.3.2.1a H5N1 HPAI, the clade circulating in Indian poultry. Species: chickens.
  • Developer: ICAR-NIHSAD, Bhopal, the national high-biosecurity animal disease institute.
  • How these vaccines work: they train the bird to make antibodies against HA. Protection is measured by the hemagglutination-inhibition (HI) antibody titre, a titre of 4 log2 or more is generally counted as positive, and by actual protection against a live-virus challenge. Both matter, because high antibodies against a different clade may not stop shedding.

Not yet disclosed: the exact production platform, seed strain, dose, schedule (number of doses, age at vaccination), duration of immunity, whether infected and vaccinated birds can be told apart (DIVA), price and when it will be available to farms.

What can we reasonably expect? Evidence from related research

Read this carefully. The studies below are published research, not the official trial data of the vaccine to be dedicated on 20 November. They show what well-matched vaccines can do. They should not be quoted as the new vaccine’s results.
StudyVaccine typeResult in chickens
ICAR-NIHSAD / IVRI (preprint, SSRN)Recombinant H5HA1 protein of clade 2.3.2.1a made in E. coli, with oil adjuvant, two boosters100% survival against clade 2.3.2.1a, 50% against clade 2.3.2.1c. HI titre of 4 log2 or more kept for 154 days after the second booster. Safe at 4 times the dose. All unvaccinated controls died within 60 hours.
Vietnam (Hoang et al., Vaccines 2020)Inactivated reverse-genetics vaccine, HA and NA of a clade 2.3.2.1c strain, single dose91.6% protection against the same clade; 83.3% against a clade 1.1 strain; all unvaccinated chickens died.

What it tells us: (1) matching the vaccine to the circulating clade is the key to high protection; (2) a good vaccine reduces deaths and virus shedding, but does not always stop shedding completely, especially against a different clade; (3) protection after vaccination needs good dose, boosters and timing, so schedule details matter.

For farmers and vets, the sensible reading is: a clade-matched inactivated vaccine is a strong new tool for reducing losses, but it supports biosecurity and surveillance, it does not replace them.

What should farmers and vets do now

  • Do not relax biosecurity. Keep visitors, vehicles and used crates out, keep wild birds and ducks away from sheds and feed, clean and disinfect between batches.
  • Report sudden high mortality to the local veterinary officer. Early reporting is what limits the loss.
  • Do not buy or use unofficial “bird flu vaccines”. Wait for the official notification on who may use it, which flocks, at what dose and schedule.
  • Plan, but do not panic-buy. Poultry vaccination policy in India has so far been based on culling. How the new vaccine will be used on farms will be decided by the authorities.
  • Watch for official announcements from ICAR-NIHSAD and the Department of Animal Husbandry and Dairying.

Our view

This section is our opinion, not a reported fact. We at IMN have long argued for a home-grown vaccine, because a country with this much poultry cannot depend only on culling. Our hope is that the vaccine is made widely available, that its field data are published openly, that vaccinated flocks stay under surveillance, and that the platform can be updated quickly when the virus changes. Backyard and duck flocks, breeders and layers should be part of the plan from the start.

Frequently asked questions

Is there a bird flu vaccine for chickens in India?
As of the PIB release of 18 November 2026, a vaccine for clade 2.3.2.1a, developed by ICAR-NIHSAD, is to be dedicated to the nation on 20 November 2026. The release says no specific commercial vaccine for this clade existed before.

Which strain does it protect against?
H5N1 clade 2.3.2.1a, the clade that has mostly been found in Indian poultry since about 2011.

Is it a live or killed vaccine?
Inactivated (killed), according to the PIB release.

What is the price and dose?
Not announced yet. We will update this page when official details are available.

Can eating chicken or eggs spread bird flu?
Cooked chicken and eggs are not considered a route when properly cooked. Human cases have mostly followed close contact with sick birds, and a recent Indian case was linked to raw chicken. Always cook poultry and eggs thoroughly.

Sources

  • Press Information Bureau, Ministry of Agriculture and Farmers Welfare, release of 18 November 2026 (PRID 2337716).
  • Boruah JLH et al., Immunogenicity and cross-protective efficacy of recombinant H5HA1 protein of clade 2.3.2.1a H5N1 virus expressed in E. coli (ICAR-NIHSAD / ICAR-IVRI), SSRN preprint 4049573.
  • Marinova-Petkova A et al., Highly pathogenic reassortant avian influenza A(H5N1) virus clade 2.3.2.1a in poultry, Bhutan. Emerging Infectious Diseases 2016;22(12).
  • Hoang HTT et al., Immunization with the H5N1 recombinant vaccine candidate induces high protection in chickens against Vietnamese HPAI virus strains. Vaccines 2020;8:159.

By Dr. Ibne Ali, IMN Pyrophos. Information here is for awareness and is not a substitute for advice from your veterinarian or the state animal husbandry department.

Scroll to Top